{"id":"NCT04969224","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)","officialTitle":"A Phase 3b Open-label Study Evaluating the Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cough and Physical Activity in Cystic Fibrosis Subjects 12 Years of Age and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-10-12","primaryCompletion":"2022-07-26","completion":"2022-07-26","firstPosted":"2021-07-20","resultsPosted":"2023-10-03","lastUpdate":"2023-10-03"},"enrollment":82,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"ELX/TEZ/IVA","otherNames":["VX-445/VX-661/VX-770","elexacaftor/tezacaftor/ivacaftor"]},{"type":"DRUG","name":"IVA","otherNames":["VX-770","ivacaftor"]}],"arms":[{"label":"ELX/TEZ/IVA","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.","primaryOutcome":{"measure":"Percent Reduction From Baseline in Cough Frequency (Cough Events Per Day) to the Average of Week 8 Through Week 12","timeFrame":"Baseline, Week 8 through Week 12","effectByArm":[{"arm":"ELX/TEZ/IVA","deltaMin":91.7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":19,"countries":["Australia","Belgium","Canada","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":81},"commonTop":["Headache","COVID-19","Nasopharyngitis","Diarrhoea","Abdominal pain"]}}